May 14 (Reuters) - Medical device maker DexCom DXCM.O said on Thursday it has agreed with activist investor Elliott Investment Management to add two independent directors to the company's board and revamp a key board committee.

Shares of the company were up about 6% in after-hours trading.

The company said it is working with Elliott to identify the new directors with medical technology and operations experience, which would bring the total number of independent directors appointed since early 2023 to six.

The appointments will be announced at a later date, the company said.

Dexcom also said its Technology Committee will be renamed the Operations and Innovation Committee, with an expanded mandate to oversee operations, quality and the company's technical roadmap.

"We also see a clear path to significant margin expansion, underpinning one of the most compelling earnings growth profiles in MedTech," said Marc Steinberg, partner at Elliott.

The development came ahead of the company's 2026 Investor Day, where it is set to outline its long-term growth and strategy.